Delivery Order SPE2DX22D0010-SPE2D823FKA61
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,543.79 firm fixed-price delivery order is for the supply of MYDAYIS ER 50 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of March 18, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $6,246.01, is for the delivery of MYDAYIS CAPS 50MG, a prescription drug product. The contract is a Firm Fixed Price Delivery Order with a completion date of June 9, 2023. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA,...
- This federal contract award, valued at $1,598.34, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and an ultimate completion date of October 30, 2024. The contract covers the supply of MYDAYIS ER 50 MG CAPSULE 100S, a pharmaceutical product, to support military healthcare programs. Amerisourcebergen holds a significant...
- This federal contract award is for the delivery of pharmaceutical products, specifically MYDAYIS ER 37.5 MG CAPSULE 100S, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $2,971.74 and is a Firm Fixed Price Delivery Order. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is not set aside and is an open competition award. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,037.41, is a delivery order (SPE2DX15D3017|SPE2DX24F0JKT) with the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency. The contract is for the supply of MYDAYIS ER 50 MG CAPSULE 100S, a pharmaceutical product. This contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,753.09 Firm Fixed Price Delivery Order contract is for the supply of MYDAYIS ER 37.5 MG CAPSULE 100S, a pharmaceutical product. The award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary...
- This is a federal contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,975.53, is a delivery order for the supply of 100 units of the drug MYDAYIS ER 50 MG CAPSULE. The contract has an ultimate completion date of February 26, 2025 and is a firm fixed-price contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp Corporate Office Division, a major pharmaceutical distributor. The $1,107.02 firm fixed price delivery order is for the supply of MYDAYIS ER 50 MG CAPSULE 100S, a prescription medication. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025, which enables the DLA to efficiently procure a comprehensive...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,324.20 fixed-price delivery order is for the supply of the medication MYDAYIS ER 12.5 MG CAPSULE 100S, with a period of performance through March 2025. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a $1,087.34 Firm Fixed Price Delivery Order placed by the Defense Logistics Agency (DLA). The contract covers the provision of MYDAYIS ER 25 MG CAPSULE 100S, a pharmaceutical product, with a period of performance through October 28, 2024. This award is not designated as a set-aside contract. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
- SPE2DX22D0010Indefinite Delivery Contract
- SPE2DX22D0010-SPE2D823FKA61Delivery Order
This federal contract award is for the delivery of pharmaceutical products, specifically "MYDAYIS CAPS 50MG," to the U.S. government. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical, a civilian agency under the Department of Defense. The contract is a firm-fixed-price delivery order with a ceiling value of $3,510.25 and a period of performance through May 9, 2023. The award is not designated as a set-aside. Amerisourcebergen Drug Corp, the prime contractor, has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 5/8/23 |